Ocular Therapeutix is currently developing an intravitreal sustained-release anti-VEGF implant in collaboration with Regeneron Pharmaceuticals designed to deliver sustained, therapeutic levels of drugs to targeted ocular tissues. The goal is to reduce the frequency of injections that are currently given monthly or bi-monthly for the treatment of serious retinal diseases and potentially extend the injection interval to once every 4 to 6 months.
Caution: NEW DRUG – OTX-IVT is currently undergoing clinical evaluation in the United States and is limited by United States law to investigational use only. This product has not been approved by the FDA as safe or effective.
Injectable shape-changing implant with a bioresorbable design.
OTX-IVT fiber to coil. Video shown in real time in simulated vitreous humor.